fbpx

Zeposia approved for MS in Scotland

Zeposia approved for MS in Scotland Published: 10 February 2021 The Scottish Medicines Consortium (SMC) has approved the drug ozanimod (Zeposia) for patients with active relapsing remitting multiple sclerosis (RRMS).  The SMC has said ozanimod can be prescribed for people who are experiencing relapses or those whose MRI scans show
Read More

Long-term fingolimod treatment may lessen disability

Long-term fingolimod treatment may lessen disability Published: 27 May 2020 Long-term treatment with fingolimod results in lesser disability in people with relapsing remitting multiple sclerosis (MS), a new study has found.  People treated with the drug for eight or more years had smaller increases in disability over the course of
Read More

Peginterferon beta-1a recommended by NICE on NHS

Peginterferon beta-1a recommended by NICE on NHS Published: 21 February 2020 Peginterferon beta-1a has been recommended as a treatment option for relapsing remitting multiple sclerosis (RRMS) by The National Institute for Health and Care Excellence (NICE) for use on the NHS in England.  Injected under the skin every two weeks,
Read More